Role of biomarkers in early detection of preeclampsia

Journal of Clinical and Diagnostic Research

Volumn 8, Issue 4, 2014, Pages

  Kar, Manisha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Early prediction; Potential biomarkers; Preeclampsia

Indexed keywords

ACTIVIN A; ALDOSTERONE; ANGIOGENIC FACTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSINOGEN; ANTIBODY; BIOLOGICAL MARKER; BRADYKININ B2 RECEPTOR; ENDOGLIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GONADOTROPIN; HLA C ANTIGEN; HLA G ANTIGEN; INHIBIN A; INTERLEUKIN 8; MICRORNA 210; NEUROKININ B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; PLACENTAL PROTEIN 13; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SOMATOMEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEREDITY; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PLACENTA; PREECLAMPSIA; PREGNANCY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPRODUCTION; SENSITIVITY AND SPECIFICITY; ULTRASOUND; VASODILATATION;

EID: 84898644224     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2014/7969.4261     Document Type: Article

References (43)

1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308: 1592-4.
2. Bolte AC, van Geijn HP, Dekker GA. Management and monitoring of severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2001; 96: 8-20.
3. Khan K S, Wojdyla D, Say L, Gulmezoglu A M, van Look P F. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367: 1066-74.
4. Berg C J, MacKay A P, Qin C, Callaghan W M. Overview of maternal morbidity during hospitalization for labor and delivery in the united states: 1993-1997 and 2001-2005. Obstetrics and Gynecology.2009; 113: 1075-81.
5. Roberts J M, Hubel C A. The two stage model of preeclampsia: variations on the theme. Placenta.2009; 30: S32-7.
6. Steegers E A P, von Dadelszen P, Duvekot J J, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376: 631-44.
7. Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007; 197(2):174.e1-5.
8. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet and Gynecol. 2000; 95: 353-7.
9. Rajakumar A, Michael H M, Rajakumar P A, et al. Extraplacental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta. 2005; 26: 563-73.
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-83.
11. Karumanchi S A, Lindheimer M D. Preeclampsia pathogenesis: "Triple a rating" autoantibodies and antiAngiogenic factors. Hypertension. 2008; 51: 991-2.
12. Mutter W P, Karumanchi S A. Molecular mechanisms of preeclampsia. Microvas Res. 2008; 75: 1-8.
13. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, et al. Urinary placental growth factor and risk of preeclampsia. JAMA.2005; 293:77-85.
14. Hagmann H, Thadhani R, Benzing T, Karumanchi S A, Stepan H. The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia. Clin Chem. 2012; 58: 837-45
15. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Intl J of Biochem and Cell Biol. 2003; 35: 881-900.
16. Fujimoto Y, Sasaki T, Tsuchida A. Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Letters. 2001; 495: 197-200.
17. Paul M, Mehr A P, Kreutz R. Physiology of local reninangiotensin systems. Physiol Reviews. 2006; 86: 747-803.
18. Redman C W, Sargent I L. Latest advances in understanding preeclampsia. Science. 2005; 308: 1592-4.
19. AbdAlla S, Lother H, Massiery A El, Quitterer U. Increased AT receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature Medicine. 2001; 7: 1003-9.
20. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT receptor. J of Clin Invest. 1999; 103: 945-52.
21. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension. 2007; 49: 612-617.
22. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14: 855-62.
23. Irani R A, Zhang Y, Blackwell S C, et al. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J of Exp Med. 2009; 206: 2809-22.
24. Zhou A, Carrell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature. 2010; 468:108-11.
25. Nicolaides KH, Bindra R, Turan OM. A novel approachbto first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006; 27: 13-7.
26. Burger O, Pick E, Zwickel J. Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. 2004; 25: 608-22.
27. Chaftez I, Kuhnreich I, Sammar M. First trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007; 197: 35.e1-35.e7.
28. Bersinger NA, Smarason AK, Muttukrishna S. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A, and soluble E-selectin. Hypertens Pregnancy. 2003; 22: 45-55.
29. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urteger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn. 2002; 22: 778-82.
30. Canini S, Prefumo F, Pastorino D. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Fertile and Steril. 2008; 89: 174-8.
31. Preiss J, Handler P. Enzymatic synthesis of nicotinamide mononucleotide. J Biol Chem. 1957; 225: 759-70.
32. Frasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol. 2007; 66: 434-9.
33. Hu W, Wang Z, Wang H, Huang H, Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynaecol Scand. 2008: 87: 413-8.
34. Frasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol. 2007; 66: 434-9.
35. Muttukrishna S, North RA, Morris J. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod. 2000; 15: 1640-5.
36. Muttukrishna S, Knight PG, Groome NP. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997; 349: 1285-8.
37. Mandang S, Maneulpillai U, Wallace EM. Oxidative stress increases placental and endothelial cell activin A secretion. J Endocrinol. 2007; 192: 485-93.
38. Davidson EJ, Riley SC, Roberts SA. Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of pre-eclampsia. Br J Obstet Gynaecol. 2003; 110: 46-52.
39. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197:28 e1-6.
40. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355: 992-1005.
41. Farina A, Zucchini C, De Sanctis P, Morano D, Sekizawa A, Purwosunu Y, et al. Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening. Prenat. Diagn. 2011; 31: 181-5.
42. Anton L, Olarerin-George AO, Schwartz N, Srinivas S, Bastek J, Hogenesch JB, et al. miR-210 Inhibits Trophoblast Invasion and Is a Serum Biomarker for Preeclampsia. Am J Pathol. 2013; Pii: S0002-9440(13)00542-7. Doi: 10.1016/j. ajpath.2013.07.021.
43. Doridot L, Houry D, Gaillard H, Chelbi ST, Barbaux S, Vaiman D. miR-34a expression, epigenetic regulation, and function in human placental diseases. Epigenetics.2013; 9 (1).